What does CoBioRes do?

CoBioRes is a research organisation in Leuven. Public Limited, started on 28 March 2013, 1 establishment.

What is the address of CoBioRes?

The registered office of CoBioRes is located at Herestraat 49 box 913, 3000 Leuven.

Is CoBioRes still active?

Yes. According to the CBE (29 October 2026) CoBioRes is active, legal situation “Normale toestand”, started on 28 March 2013.

Is CoBioRes registered on Peppol?

Yes, CoBioRes is registered on the Peppol network with ID 0208:0525845116.

What is the enterprise number of CoBioRes?

The enterprise number of CoBioRes is BE0525845116.

When was CoBioRes founded?

CoBioRes was founded on 28 March 2013.

Who are the directors of CoBioRes?

According to the 2025 annual accounts, the directors of CoBioRes are: Desire COLLEN, SOFIA BVBA.

Is CoBioRes a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 March 2013; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CoBioRes make in 2025?

CoBioRes recorded a loss after taxes of € 28,827 in financial year 2025.

What is the revenue of CoBioRes?

As a small company, CoBioRes is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -28,361.

CoBioRes (Public Limited) - Leuven - BE0525845116

Dossier CoBioRes, printed on 29 October 2026 from databakkes.be/en/0525845116/cobiores. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Busy address KBO

57 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

CoBioRes from Leuven, company number BE0525845116, closed financial year 2025 with a result of € -28,827 after tax. For that financial year CoBioRes recorded a gross margin of € -28,361 and equity of € 337,767. Compared with financial year 2024, the result moved from € -9,658 to € -28,827. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Healthy

€ 337,767

▼ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -28,827

▼ 198 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 248,783

▲ 51% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -7.7 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 247

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -56,959 Gross margin 2022: € -56,959 First fiscal year in the series	€ -48,357 Gross margin 2023: € -48,357 ▲ € 8,602 vs 2022 (€ -56,959) Favourable step	€ -10,249 Gross margin 2024: € -10,249 ▲ € 38,108 vs 2023 (€ -48,357) Favourable step	€ -28,361 Gross margin 2025: € -28,361 ▼ € 18,112 vs 2024 (€ -10,249) Unfavourable step	▼ € 18,112
Profit after taxes	€ -63,215 Profit after taxes 2022: € -63,215 First fiscal year in the series	€ -52,916 Profit after taxes 2023: € -52,916 ▲ € 10,299 vs 2022 (€ -63,215) Favourable step	€ -9,658 Profit after taxes 2024: € -9,658 ▲ € 43,258 vs 2023 (€ -52,916) Favourable step	€ -28,827 Profit after taxes 2025: € -28,827 ▼ € 19,169 vs 2024 (€ -9,658) Unfavourable step	▼ € 19,169
Equity	€ 429,167 Equity 2022: € 429,167 First fiscal year in the series	€ 376,251 Equity 2023: € 376,251 ▼ 12% vs 2022 (€ 429,167) Unfavourable step	€ 366,593 Equity 2024: € 366,593 ▼ 3% vs 2023 (€ 376,251) Unfavourable step	€ 337,767 Equity 2025: € 337,767 ▼ 8% vs 2024 (€ 366,593) Unfavourable step	▼ 8%
Total debts	€ 0 Total debts 2022: € 0 First fiscal year in the series	€ 4,376 Total debts 2023: € 4,376 Unchanged (€ 0) Unfavourable step	€ 0 Total debts 2024: € 0 ▼ 100% vs 2023 (€ 4,376) Favourable step	€ 247 Total debts 2025: € 247 Unchanged (€ 0) Unfavourable step
Cash	€ 92,860 Cash 2022: € 92,860 First fiscal year in the series	€ 112,803 Cash 2023: € 112,803 ▲ 21% vs 2022 (€ 92,860) Favourable step	€ 165,215 Cash 2024: € 165,215 ▲ 46% vs 2023 (€ 112,803) Favourable step	€ 248,783 Cash 2025: € 248,783 ▲ 51% vs 2024 (€ 165,215) Favourable step	▲ 51%
Retained profit	€ -7,570,833 Retained profit 2022: € -7,570,833 First fiscal year in the series	€ -7,623,749 Retained profit 2023: € -7,623,749 ▼ € 52,916 vs 2022 (€ -7,570,833) Unfavourable step	€ -7,633,407 Retained profit 2024: € -7,633,407 Unchanged (€ -7,623,749) Unfavourable step	€ -7,662,233 Retained profit 2025: € -7,662,233 Unchanged (€ -7,633,407) Unfavourable step
Balance sheet total	€ 429,167 Balance sheet total 2022: € 429,167 First fiscal year in the series	€ 380,627 Balance sheet total 2023: € 380,627 ▼ 11% vs 2022 (€ 429,167) Unchanged	€ 366,593 Balance sheet total 2024: € 366,593 ▼ 4% vs 2023 (€ 380,627) Unchanged	€ 338,014 Balance sheet total 2025: € 338,014 ▼ 8% vs 2024 (€ 366,593) Unchanged	▼ 8%

Key figures of CoBioRes, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CoBioRes?

What happened at CoBioRes in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 Desire COLLEN stepped down as director. NBB
2028 SOFIA BVBA stepped down as director. NBB
Jul 1, 2026 New annual accounts for financial year 2025: loss of € 28,827. Source: NBB ↗
2022 Desire COLLEN became a director. NBB
2022 SOFIA BVBA became a director. NBB
Mar 28, 2013 New establishment in Leuven. KBO
Mar 28, 2013 Start of the company according to the CBE. KBO

In short

From € 63,215 loss in 2022 to € 28,827 loss in 2025.

Paid € 1,019 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

Management

Life Sciences Research Partners 100%

The stake of Life Sciences Research Partners comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CoBioRes

The shares are held by Life Sciences Research Partners (100%).

Directors

According to the 2025 annual accounts

Desire COLLEN

Chairman of the board

Also active at: Life Sciences Research Partners, PATCOBEL

since 2022 · until 2028

SOFIA BVBA

Director · represented by Chris BUYSE

Also active at: Life Sciences Research Partners

since 2022 · until 2028

Shareholders

Life Sciences Research Partners

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Herestraat 49 box 913

3000 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 57 companies are registered at this address.

All companies at this address →

The Association for European Paediatric and Congenital Cardiology

Stfran.

€ 75,987 revenue · 2023

ALFAGEN: Alumni van de FAculteit GENeeskunde KU Leuven

Rega Instituut

€ -7,459 gross margin · 2025

Vlaamse Vereniging voor Seksuologie

+52 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0525.845.116

VAT number

BE 0525.845.116

Registered office

Herestraat 49 bus 913, 3000 Leuven

Names & denominations

CoBioRes

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 March 2013

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

CoBioRes

Warning lights

Financials

What happened to CoBioRes?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions